Characterization of Glycometabolism and Tumor Immune Microenvironment for Predicting Clinical Outcomes in Gastric Cancer

Overview

Journal iScience

Publisher Cell Press

Date 2023 Mar 14

PMID 36915686

Authors

Jinyao Shi

Zhouqiao Wu

Xiaolong Wu

Longtao Huangfu

Ting Guo

Xiaojing Cheng

Jing Han

Ziyu Li

Xiaofang Xing

Jiafu Ji

Affiliations

Soon will be listed here.

Abstract

Recent evidence demonstrates that the reprogramming of energy metabolism can interact with the tumor immune microenvironment, thereby participating in the progression of cancer. In this study, multi-omics data of 2471 gastric cancer samples were used to identify tumor glycometabolism and its correlation with tumor immune microenvironment. A series of bioinformatic approaches were performed to establish a scoring system to predict the survival and response of chemotherapy and immunotherapy. Three glycometabolic subtypes and two immune clustering subgroups of gastric cancer were determined. We further established a Gluco-Immune Scoring system to quantify the cancer glycometabolic status and immune infiltration of individual patients. Patients with low Gluco-Immune Score were sensitive to adjuvant chemotherapy, while patients with high Gluco-Immune Score may benefit from immunotherapy. Our results indicate that in gastric cancer, the assessment of tumor glucose metabolism and immune microenvironment has application value for the prediction of curative effects and the formulation of combined treatment strategies.

Citing Articles

Polymorphism rs2327430 in TCF21 predicts the risk and prognosis of gastric cancer by affecting the binding between TFAP2A and TCF21.

Zhou X, Shen K, Cao S, Li P, Xiao J, Dong J Cancer Cell Int. 2024; 24(1):159.

PMID: 38714991 PMC: 11075239. DOI: 10.1186/s12935-024-03343-z.

Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development.

Yasuda T, Wang Y Trends Cancer. 2024; 10(7):627-642.

PMID: 38600020 PMC: 11292672. DOI: 10.1016/j.trecan.2024.03.008.

Immunotherapy and Cancer: The Multi-Omics Perspective.

Donisi C, Pretta A, Pusceddu V, Ziranu P, Lai E, Puzzoni M Int J Mol Sci. 2024; 25(6).

PMID: 38542536 PMC: 10971308. DOI: 10.3390/ijms25063563.

Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.

Hou W, Zhao Y, Zhu H Int J Mol Sci. 2023; 24(20).

PMID: 37895000 PMC: 10607383. DOI: 10.3390/ijms242015321.

Rs15285, a functional polymorphism located in lipoprotein lipase, predicts the risk and prognosis of gastric cancer.

Shen K, Zhou X, Hu L, Xiao J, Cheng Q, Wang Y Appl Microbiol Biotechnol. 2023; 107(10):3243-3256.

PMID: 37036527 DOI: 10.1007/s00253-023-12505-4.

References

Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G . Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020; 10(15):7002-7014. PMC: 7295060. DOI: 10.7150/thno.46176. View

Zemek R, de Jong E, Chin W, Schuster I, Fear V, Casey T . Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. Sci Transl Med. 2019; 11(501). DOI: 10.1126/scitranslmed.aav7816. View

Vukovic V, Tannock I . Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer. 1997; 75(8):1167-72. PMC: 2222779. DOI: 10.1038/bjc.1997.201. View

Kohanbash G, Carrera D, Shrivastav S, Ahn B, Jahan N, Mazor T . Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017; 127(4):1425-1437. PMC: 5373859. DOI: 10.1172/JCI90644. View

Liu Y, Lin P, Zhao Y, Wu L, Wu Y, Peng J . Pan-cancer analysis of clinical significance and associated molecular features of glycolysis. Bioengineered. 2021; 12(1):4233-4246. PMC: 8806880. DOI: 10.1080/21655979.2021.1955510. View

Thi Hanh Phi L, Sari I, Yang Y, Lee S, Jun N, Kim K . Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018; 2018:5416923. PMC: 5850899. DOI: 10.1155/2018/5416923. View

Anderson N, Mucka P, Kern J, Feng H . The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2017; 9(2):216-237. PMC: 5818369. DOI: 10.1007/s13238-017-0451-1. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

Xiao Z, Dai Z, Locasale J . Metabolic landscape of the tumor microenvironment at single cell resolution. Nat Commun. 2019; 10(1):3763. PMC: 6704063. DOI: 10.1038/s41467-019-11738-0. View

10.

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

11.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

12.

Huang H, Wen X, Xue H, Chen R, Ji J, Xu L . Phosphoglucose isomerase gene expression as a prognostic biomarker of gastric cancer. Chin J Cancer Res. 2019; 31(5):771-784. PMC: 6856704. DOI: 10.21147/j.issn.1000-9604.2019.05.07. View

13.

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View

14.

Li F, Liu J, Bao R, Yan G, Feng X, Xu Y . Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun. 2018; 9(1):508. PMC: 5802808. DOI: 10.1038/s41467-018-02950-5. View

15.

Cai L, Hu C, Yu S, Liu L, Yu X, Chen J . Identification and validation of a six-gene signature associated with glycolysis to predict the prognosis of patients with cervical cancer. BMC Cancer. 2020; 20(1):1133. PMC: 7686733. DOI: 10.1186/s12885-020-07598-3. View

16.

Xing X, Jia S, Leng Y, Wang Q, Li Z, Dong B . An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer. Oncoimmunology. 2020; 9(1):1792038. PMC: 7470183. DOI: 10.1080/2162402X.2020.1792038. View

17.

Kim S, Cristescu R, Bass A, Kim K, Odegaard J, Kim K . Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z. View

18.

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

19.

Phan T, Croucher P . The dormant cancer cell life cycle. Nat Rev Cancer. 2020; 20(7):398-411. DOI: 10.1038/s41568-020-0263-0. View

20.

Fitzwalter B, Towers C, Sullivan K, Andrysik Z, Hoh M, Ludwig M . Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell. 2018; 44(5):555-565.e3. PMC: 5866042. DOI: 10.1016/j.devcel.2018.02.014. View